Download PDF
CC BY-NC-ND 4.0 · Ibnosina Journal of Medicine and Biomedical Sciences 2019; 11(01): 25-28
DOI: 10.4103/ijmbs.ijmbs_3_19
Original Article

Prevalence and risk factors of diabetic peripheral neuropathy in patients with Type 2 diabetes mellitus

Abdulwahab Elbarsha
1   Department of Medicine, Faculty of Medicine, University of Benghazi, Benghazi
2   Department of Medicine, Benghazi Medical Center, Benghazi
,
Mohamed Hamedh
1   Department of Medicine, Faculty of Medicine, University of Benghazi, Benghazi
2   Department of Medicine, Benghazi Medical Center, Benghazi
,
Muftah Elsaeiti
1   Department of Medicine, Faculty of Medicine, University of Benghazi, Benghazi
3   Department of Medicine, Hawari General Hospital, Benghazi
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Background: Diabetic peripheral neuropathy (DPN) is common among people with diabetes and can result in foot ulceration and amputation. Objective: The objective of the study is to estimate the prevalence and risk factors of DPN among patients with Type 2 diabetes mellitus (T2DM) at a diabetes clinic in Benghazi Medical Center (BMC), Benghazi, Libya. Patients and Methods: Three hundred and sixty-seven patients with T2DM (127 [34.6%] males and 240 [65.4%] females) were included in this cross-sectional study. The patients aged ≥18 years, and they attended the outpatient diabetes clinics at BMC from May 2015 to October 2016, for routine follow-up. Patients with T1DM, gestational diabetes, and latent autoimmune diabetes in adults were excluded. Data including gender, age, type of DM, duration of DM, history of smoking, history of hypertension, weight, height, glycosylated hemoglobin (HbA1c), total cholesterol, triglyceride, low-density lipoprotein, high-density lipoprotein, creatinine, and urea were obtained by a prepared pro forma. Peripheral neuropathy was diagnosed in the presence of numbness, paresthesia, 10-g monofilament examination, and loss of vibration and joint position sensations. The relationship between DPN and its risk factors, in addition to independent predictors of DPN, was explored using multiple forward stepwise logistic regression and presented as an odds ratio (OR) and 95% confidence interval (CI). Results: The prevalence of DPN was 30.5% in the studied group. A statistical significant association found between DPN and age (P = 0.014), duration of DM (P < 0.001), macrovascular complications of DM (P < 0.001), diabetic retinopathy (P = 0.001), diabetic nephropathy (P < 0.001), poor glycemic control (high HbA1c) (P < 0.001), hypertension (P = 0.011), uncontrolled blood pressure (≥140/90 mmHg) (P = 0.007), and insulin treatment (P < 0.001). Multiple forward stepwise logistic regression analyses revealed two independent risk factors influencing DPN: diabetic nephropathy (OR = 1.976, 95% CI: 1.289–3.027) (P = 0.009) and insulin treatment (OR = 3.430, 95% CI: 2.021–5.821), (P < 0.001). Conclusions: The overall prevalence rate of DPN in this study was 30.5% among patients with T2DM. It increases with the presence of diabetic nephropathy and insulin treatment.

Key-words:

Diabetes mellitus - diabetic peripheral neuropathy - prevalence - risk factors

Financial support and sponsorship

Nil.




Publication History

Received: 09 January 2019

Accepted: 19 January 2019

Article published online:
07 July 2022

© 2019. The Libyan Authority of Scientific Research and Technologyand the Libyan Biotechnology Research Center. All rights reserved. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License,permitting copying and reproductionso long as the original work is given appropriate credit. Contents may not be used for commercial purposes, oradapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Guariguata L, Whiting D, Weil C, Unwin N. The international diabetes federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. Diabetes Res Clin Pract 2011;94:322-32.
  • 2 Beshyah SA. Non-communicable diseases and diabetes care guidelines: Epidemiology and call for collective action. February, 6th 2010, Dat Elmad Conference Hall Complex, Tripoli, Libya. Ibnosina J Med Biomed Sci 2010;2:142-8.
  • 3 Kadiki OA, Roaeid RB. Prevalence of diabetes mellitus and impaired glucose tolerance in Benghazi Libya. Diabetes Metab 2001;27:647-54.
  • 4 Nicolucci A, Carinci F, Cavaliere D, Scorpiglione N, Belfiglio M, Labbrozzi D, et al. Ameta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian study group. The st. Vincent declaration. Diabet Med 1996;13:1017-26.
  • 5 Buzaid N, Nagem F. Characteristics of diabetic foot disease and risk factors in Benghazi, Libya. Ibnosina J Med Biomed Sci 2018;10:165-8.
  • 6 Lehtinen JM, Uusitupa M, Siitonen O, Pyörälä K. Prevalence of neuropathy in newly diagnosed NIDDM and nondiabetic control subjects. Diabetes 1989;38:1307-13.
  • 7 Harris M, Eastman R, Cowie C. Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care 1993;16:1446-52.
  • 8 Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-24.
  • 9 Dyck PJ, Karnes JL, O'Brien PC, Litchy WJ, Low PA, Melton LJ 3rd, et al. The Rochester Diabetic Neuropathy Study: Reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992;42:1164-70.
  • 10 Palumbo PJ, Elveback LR, Whisnant JP. Neurologic complications of diabetes mellitus: Transient ischemic attack, stroke, and peripheral neuropathy. Adv Neurol 1978;19:593-601.
  • 11 Pirart J. Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978;1:168-88.
  • 12 Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36:150-4.
  • 13 Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM complications study. Diabetologia 1996;39:1377-84.
  • 14 Cabezas-Cerrato J. The prevalence of clinical diabetic polyneuropathy in Spain: A study in primary care and hospital clinic groups. Neuropathy Spanish Study Group of the Spanish Diabetes Society (SDS). Diabetologia 1998;41:1263-9.
  • 15 Thomas P, Eliasson S. Diabetic neuropathy. Periphe Neuropathy 1984;2:1773-810.
  • 16 Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ 3rd, O'Brien PC, et al. Risk factors for severity of diabetic polyneuropathy: Intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999;22:1479-86.
  • 17 Kadiki OA, Roaed RB. Epidemiological and clinical patterns of diabetes mellitus in Benghazi, Libyan Arab Jamahiriya. East Mediterr Health J 1999;5:6-13.
  • 18 Wang DD, Bakhotmah BA, Hu FB, Alzahrani HA. Prevalence and correlates of diabetic peripheral neuropathy in a Saudi Arabic population: A cross-sectional study. PLoS One 2014;9:e106935.
  • 19 Halawa MR, Karawagh A, Zeidan A, Mahmoud AE, Sakr M, Hegazy A, et al. Prevalence of painful diabetic peripheral neuropathy among patients suffering from diabetes mellitus in Saudi Arabia. Curr Med Res Opin 2010;26:337-43.
  • 20 Gregg EW, Sorlie P, Paulose-Ram R, Gu Q, Eberhardt MS, Wolz M, et al. Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 National Health and Nutrition Examination Survey. Diabetes Care 2004;27:1591-7.
  • 21 Rate RG, Knowler WC, Morse HG, Bonnell MD, McVey J, Chervenak CL, et al. Diabetes mellitus in Hopi and Navajo Indians. Prevalence of microvascular complications. Diabetes 1983;32:894-9.
  • 22 Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M, et al. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:89-94.
  • 23 Börü UT, Alp R, Sargin H, Koçer A, Sargin M, Lüleci A, et al. Prevalence of peripheral neuropathy in type 2 diabetic patients attending a diabetes center in Turkey. Endocr J 2004;51:563-7.
  • 24 Kiani J, Moghimbeigi A, Azizkhani H, Kosarifard S. The prevalence and associated risk factors of peripheral diabetic neuropathy in Hamedan, Iran. Arch Iran Med 2013;16:17-9.
  • 25 Mold JW, Vesely SK, Keyl BA, Schenk JB, Roberts M. The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients. J Am Board Fam Pract 2004;17:309-18.
  • 26 Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs. other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 2013;98:668-77.